THIS PAGE IS INSERTED BY OIPE SCANNING AND IS NOT PART OF THE OFFICIAL RECORD

Best Available Images

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

BLACK BORDERS

TEXT CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT

BLURRY OR ILLEGIBLE TEXT

SKEWED/SLANTED IMAGES


COLORED PHOTOS HAVE BEEN RENDERED INTO BLACK AND WHITE

VERY DARK BLACK AND WHITE PHOTOS

UNDECIPHERABLE GRAY SCALE DOCUMENTS

IMAGES ARE THE BEST AVAILABLE COPY. AS RESCANNING WILL NOT CORRECT IMAGES, PLEASE DO NOT REPORT THE IMAGES TO THE PROBLEM IMAGE BOX.

FIGURE 1A



ii P

FIGURE 1B




FIGURE 1C.




FIGURE 1'D




FIGURE 2



FIGURE 3



Setting stage, port and max speed.

FIGURE 4



Output trigger settings.


FIGURE 5



FIGURE 6A



FIGURE 6B







FIGURE 7

Stage Settin	gs		X
main settings			
stage type: Virtual test stage	COM2	maxuncun speed	(microns/second)
output tirigger		and the second	
type rising	gin. ⊋ 0	duration (millise	conds) (intest
input trigger type	Din 355	The second secon	
ising and a second seco	1		je jest k
Рипрожинае ч			
	165		ik Cancel

FIGURE 8



FIGURES 9A-C




FIGURE 10 A-C




FIGURE 11A-G





FIGURE 11H-N

Top View



Side View




FIGURE 12A-C

Channel content	В	71	17	T3	В	αl	В	a 2	В	a 3	В	a 4	В	72	В	α 5	В	a 6	В	α 7	В	8	В	Τι	T2	T3
Chann el#	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26

 $Simulated\ trace\ for\ a\ single\ forward\ scan\ across\ microfluidic\ channel\ outlets:$




FIGURE 13A-B

Score sheet (mean peak current amplitude of 6 scans)

Receptor response	0	1	5	10	0	0	0	12	0	0	0	0	0	5	0	0	0	37	0	0	0	0	0	1	5	10
Channel #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	.21	22	23	24	25	26

T1= Test compound with known efficacy (agonist) at low concentration
T2= Test compound with known efficacy (agonist) at medium concentration (close to EC₅₀-value)
T3= Test compound with known efficacy (agonist) at high concentration (saturating concentration).
α=agonist with unknown efficacy

FIGURE 13C

Channel	В	Tl	T2	T3	αΙ	α2	α3	α4	α5	α6	α7	Tl	T2	T3
content							l							
Channel #	1	2	3	4	5	6	7	8	9	10	11	12	13	14

Simulated trace for a single forward scan across microfluidic channel outlets.




FIGURE 14A-B

FIGURE 14C

Score sheet (mean peak current amplitude of 6 scans)

Receptor response	0	5	10	20	0	0	34	0	4	0	0	5	10	20	Ì
Channel #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	

B=Buffer solution

T1= Test compound with known efficacy (agonist) at low concentration
T2= Test compound with known efficacy (agonist) at medium concentration (close to EC₅₀-value)
T3= Test compound with known efficacy (agonist) at high concentration (saturating concentration). α=agonist with unknown efficacy

Content	В	TI	172	TT	T B	ai	B	1 =	Ta.	Τ-	Тъ	-	В	-	B	,	-											
in	1	l	l	3		"	1	2	1	3	"	4	1 "	172	ľ	5	В	1 6	1 "	α7	В	a 8	В	Tn T	172	ייון	В	യ
channel	_	L	L_	<u>_</u>	l	1	L_		_	1	!	1				1		ľ	1	1	l		i	1	ĺ	,	1	1
Channel #	l'	2	3	٦.	5	6	7	1	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28
Content in channel	В	71	72	3	α 20	B	a 19	В	13	В	a 17	В	a 16	В	15	В	72	В	α 14	В	α 13	В	α 12	В	a 11	В	10	В
Channel #	56	55	54	53	52	51	50	49	48	47	46	45	44	43	42	41	40	39	38	37	36	35	34	33	32	31	30	29

Simulated trace for a single forward scan across microfluidic channel outlets:



FIGURE 15A-B

Score sheet (mean peak current amplitude of 6 scans)

Receptor response	0	1	5	10	0	0	0	0	0	0	0	0	0	5	0	0	0	0	0	0	0	0	0	1	5	10	0	TT
,			l		ļ				l	i			•		1													
Channel #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28
Receptor response	0	7	5	10	36	0	35	0	32	0	27	0	24	0	15	0	5	0	12	0	8	0	6	0	3	0	2	0
Channel	56	55	54	53	52	51	50	49	48	47	46	45	44	43	42	41	40	39	38	37	36	35	34	33	32	31	30	29

B=Buffer solution

T1= Test compound with known efficacy (antagonist or agonist) at low concentration

T2= Test compound with known efficacy (antagonist or agonist) at medium concentration (close to EC50-value)

T3= Test compound with known efficacy (antagonist or agonist) at high concentration (saturating concentration). α 1-to- α 28 agonist with unknown efficacy at different concentration progressively diluted (each step 10 times) to α 1

FIGURE 15C

Channel content	B +	T 1+	T 2+	T 3+	B +	Α +ζ	B +	Α +ζ	B +	Α +ζ	B +	Α +ζ	B +	T2 +	B +	Α +ζ	B +	Α +ζ	B +	Α +ζ	B+ A	A+ ζ8	B+ A	Tì	T2	T3
Channel #	î	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26

Simulated trace for a single forward scan across microfluidic channel outlets:




FIGURE 16A-B

Score sheet (mean peak current amplitude of 6 scans)

, [Receptor response	20	10	5	1	20	20	20	20	20	1	20	20	20	5	20	15	20	20	20	20	20	20	20	10	5	1
L	Channel #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26

B=Buffer solution
T1= Test compound with known efficacy (antagonist) at low concentration
T2= Test compound with known efficacy (antagonist) at medium concentration (close to EC₅₀-value)
T3= Test compound with known efficacy (antagonist) at high concentration (saturating concentration).
A=agonist with known efficacy
ζ=antagonist with unknown efficacy

FIGURE 16C




Figure 17




FIGURE 18

